CoChat

TGF-β Inhibition and Immunotherapy: Checkmate

Open access
Ganesh, Karuna, Massagué, Joan · 2018 · Immunity
Cited by 124

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary Immune checkpoint therapy can induce durable remissions, but many tumors demonstrate resistance. Mariathasan et al., and Tauriello et al., identify stromal TGFβ signaling as a determinant of immune exclusion. Combination TGFβ inhibition and immunotherapy induces complete responses in mouse models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2018.03.037

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Cancer immunotherapy using checkpoint blockade

    Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

  • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

    Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 5×

    “Mariathasan et al. sought to identify biomarkers of clinical response to the PD-L1 antagonist atezolizumab in a phase 2 trial of metastatic urothelial cancer (mUC). mUC is a carcinogendriven tumor with high TMB, and five immune checkpoint inhibitors have been FDA approved as first-line or second-line treatment, althou…”
    ResultInfluential
  • TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

    Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 7×

    “Tauriello et al. contribute further depth to the analysis of TGFβ in immunotherapy response by using a sophisticated array of genetically engineered and organoid transplantation mouse models of metastatic colorectal cancer (CRC).”
    ResultInfluential
  • Predictive biomarkers for checkpoint inhibitor-based immunotherapy

    Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · cited 2×

    “Studies in melanoma, non-small cell lung cancer and colorectal cancer, among others, have identified the presence of a tumor immune infiltrate, high tumor mutation burden (TMB), microsatellite instability, and PD-L1 expression as biomarkers of response to PD-1/PD-L1 blockade in some patients (Gibney et al., 2016).”
    Background
  • Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

    Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070 · cited 2×

    “A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript TGFβ signaling, as well as high RNA expression of the TGFβ driven CRC consensus molecular signature 4, which has been associated with poor prognosis in patients (Calon et al., 2015).”
    Background

Cited by

See all 124

Metadata

Authors
Ganesh, K., & Massagué, J.
Venue
Immunity
Publisher
Elsevier BV
Published
2018-04
Volume
48
Issue
4
Pages
626-628
ISSN
1074-7613 (ISSN-L)
OpenAlex
W2801211626
Cited by
124
References
5
FWCI
6.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.